Abstract: Novel 3-phenylpropanoic acid compounds have the general formula (I) below: and are formulated into pharmaceutical compositions for administration in human or veterinary medicine (in dermatology, and also in the field of cardiovascular diseases, immune diseases and/or lipid metabolism-related diseases), or, alternatively, into cosmetic compositions.

Abstract: Novel 3-phenyl acrylic acid compounds have the following general formula (I): and are formulated into pharmaceutical compositions for administration in human or veterinary medicine (in dermatology, as well as in the field of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or into cosmetic compositions.

Abstract: Vitamin D derivatives, notably non-steroidal vitamin D derivatives, are prepared from novel disubstituted phenylboronic acid compounds having the formula (I): and also from the novel intermediates having the formulae (1), (2), (3) and (10):

Abstract: Vitamin D derivatives, notably non-steroidal vitamin D derivatives, are prepared from novel disubstituted phenylboronic acid compounds having the formula (I): and also from the novel intermediates having the formulae (1), (2), (3) and (10):

Abstract: Vitamin D derivatives, notably non-steroidal vitamin D derivatives, are prepared from novel disubstituted phenylboronic acid compounds having the formula (I): and also from the novel intermediates having the formulae (1), (2), (3) and (10):

Abstract: 3-[5?-(3,4-bis(hydroxymethyl)benzyloxy)-2?-ethyl-2-propylbiphenyl-4-yl]pentan-3-ol is prepared from the novel intermediate, 6-ethyl-4?-(1-ethyl-1-hydroxypropyl)-2?-propylbiphenyl-3-ol.

Abstract: A novel method for preparing 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid includes a Suzuki reaction between 3-adamantyl-4-methoxyphenylboronic acid of formula (II): and 6-bromo-2-naphthoic acid of formula (III):

Abstract: A novel method for preparing 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid includes a Suzuki reaction between 3-adamantyl-4-methoxyphenylboronic acid of formula (II): and 6-bromo-2-naphthoic acid of formula (III):

Abstract: Novel 7,7-disubstituted (5H,9H)-6,8-dioxabenzocycloheptene compounds having the structural formula (I): are useful intermediates in the synthesis of non-steroidal derivatives of vitamin D.

Abstract: 3-[5?-(3,4-bis(hydroxymethyl)benzyloxy)-2?-ethyl-2-propylbiphenyl-4-yl]pentan-3-ol is prepared from the novel intermediate, 6-ethyl-4?-(1-ethyl-1-hydroxypropyl)-2?-propylbiphenyl-3-ol

Abstract: Novel 7,7-disubstituted (5H,9H)-6,8-dioxabenzocycloheptene compounds having the structural formula (I): are useful intermediates in the synthesis of non-steroidal derivatives of vitamin D.

Abstract: Vitamin D derivatives, notably non-steroidal vitamin D derivatives, are prepared from novel disubstituted phenylboronic acid compounds having the formula (I): and also from the novel intermediates having the formulae (1), (2), (3) and (10):

Abstract: 5-aryl-1H-triazole compounds of the formula are potent and selective COX-2 inhibitors. The invention further relates to pharmaceutical compositions containing these compounds.

Abstract: Imidazole derivatives of the formula: in which R1 and R2 are each independently hydrogen, (C1-C6)alkyl or (C3-C8)cycloalkyl; n is 0, 1 or 2; R3, R4, R5 and R6 are each independently hydrogen or a (C1-C6)alkyl, halogen, cyano, (C1-C6)alkoxy, trifluoromethyl, (C1-C6)alkylthio, (C1-C6)alkylsulfonyl, sulfonamido, acyl, (C1-C6)alkoxycarbonyl, or carboxamido group; R3 and R6 together with the phenyl ring bearing them can also form a benzofurane, or a N-methylbenzotriazole. The invention also relates to pharmaceutical compositions containing these derivatives, and to the uses thereof.

Abstract: The invention relates to precursors of the A-ring of vitamin D, of the formula (I): in which A, R, R1 and R2 are as defined in the specification. The invention also relates to a method of preparing compounds (I) comprising the enzymatic asymmetrization of 3,5-dihydroxybenzoic acid derivatives, as well as intermediates of preparation of said compounds.

Abstract: A wedge box of alveolar material having a container and a lid. The container or the lid includes a window which is transparent and which is integrated and molded in the alveolar material to permit viewing the contents of the box. The box is molded by means of a mold having two cavities which include several raised surfaces. The raised surfaces are separated by a space which permit gripping of a transparent member which is to be integrated into the box as a window. Alveolar material is introduced into the molding cavity and is then expanded.

Abstract: The invention relates to compounds of the formula: in which R1, R2, R3, R4, R5, R6, n and X are as defined in the specification, and to pharmaceutical compositions containing them. These compounds are excellent progestogens which are devoid of residual androgenic activity.

Abstract: Compounds of the formula: ##STR1## wherein: m is 0 or 1;R.sup.1 is hydrogen, hydroxy, or lower alkyl;R.sup.2 is hydrogen, or lower alkyl;R.sup.3 is ##STR2## or R.sup.2 and R.sup.3 taken together with the nitrogen atom to which they are attached represent a group of the formula: ##STR3## wherein: n is 0 or 1;p is 0, 1, 2 or 3;q is 0 or 1;R.sup.4 is hydrogen, lower alkyl, cycloalkyl, or optionally substituted phenyl;R.sup.5 is optionally substituted phenyl;X is (CH.sub.2).sub.p, or 4-piperidin-1-yl;Y is CH, CH--O--, CH--S--, or nitrogen;Z is CH.sub.2, NH, sulfur, or oxygen; andA is a substituted furanyl group.

Abstract: Compounds of the formula: ##STR1## wherein A, R.sup.1, R.sup.2, R.sup.3 and m are defined as in the specification or a pharmaceutically acceptable acid addition salt or N-oxide thereof, are calcium and sodium channel antagonists useful for treating mammals having a variety of disease states, such as stroke, epilepsy, hypertension, angina, migraine, arrhythmia, thrombosis, embolism, and also for treatment of spinal injuries.

Abstract: The invention provides a new and efficient process for preparing 2,4(5)-substituted or 1,2,4-substituted imidazole derivatives.The invention also provides a process for preparing substituted aminoalkylimidazole derivatives, useful for the treatment of mammals having a variety of disease states, including stroke, epilepsy, hypertension, angina, migraine, arrhythmia, thrombosis, embolism, and the like.